Showing 1511-1520 of 3763 results for "".
Does Diet Matter in Management of Psoriasis?
https://practicaldermatology.com/topics/psoriasis/does-diet-matter-in-management-of-psoriasis/19653/Ronald Prussick, MD says there are dietary changes patients with psoriasis can make to potentially help manage their disease and lower their BMI, which can help improve psoriasis symptoms. He shares some tips and discusses when a referral to a registered dietician makes sense.Developing PsA: Risk Factors for Psoriasis Patients
https://practicaldermatology.com/topics/psoriasis/developing-psa-risk-factors-for-psoriasis-patients/19651/Can patients with psoriasis lessen their chance of developing psoriatic arthritis? Ronald Prussick, MD discusses the known risk factors and the importance of weight and a low BMI for these patients. He also talks about non-alcoholic fatty liver syndrome in this patient population.Itching for Answers: Understanding and Treating Pruritus
https://practicaldermatology.com/topics/general-topics/itching-for-answers-understanding-and-treating-pruritus/18493/Since childhood, when he was affected by eczema and associated pruritus, Ethan Lerner, MD, PhD has been fascinated by itch, its causes, and its potential treatments. In this edition of Benchside Dispatches, he offers a fresh look at the latest research on pruritus and the challenges facing scientistTopical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oFDA Follow-Up Study Reignites Sunscreen Safety Debate
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/fda-follow-up-study-reignites-sunscreen-safety-debate/23219/CSF faculty weigh in on the meaning of recent sunscreen studies.Your Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/practice-management/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/20903/DermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraHyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaSkin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancUpdates on AD Therapeutics
https://practicaldermatology.com/topics/atopic-dermatitis/updates-on-ad-therapeutics/19760/It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And the